ImmunoPrecise Antibodies (CVE:IPA) Stock Price Up 0.8% – Time to Buy?

Shares of ImmunoPrecise Antibodies Ltd. (CVE:IPA) traded up 0.8% on Tuesday . The stock traded as high as C$6.70 and last traded at C$6.50. 19,980 shares traded hands during trading, an increase of 3% from the average daily volume of 19,376 shares. The stock had previously closed at C$6.45.

ImmunoPrecise Antibodies Trading Up 0.8%

The company has a quick ratio of 4.29, a current ratio of 5.06 and a debt-to-equity ratio of 1.70. The business’s fifty day moving average is C$6.50 and its 200-day moving average is C$6.50. The stock has a market capitalization of C$162.08 million and a PE ratio of -7.30.

ImmunoPrecise Antibodies Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.